In the present study, we tried to detect ferritin-secreting cells (FSC) as plaque-forming cells using a reverse hemolytic plaque assay and thereby to evaluate some of the cellular aspects of ferritin dynamics associated with various hematological disorders. Healthy adult males had 433 FSC and adult females had 244 FSC in 1 × 105 peripheral blood mononuclear cells (PBM). The mean numbers of FSC in 1 × 105 lymphocyte-enriched fraction were 120 in males and 53 in females, and those in 1 × 105 monocyte-enriched fraction were 932 in males and 668 in females. These results indicate that monocytes contain about 8–13 times as many FSC as lymphocytes. Each fraction of PBM from patients with iron deficiency anemia contains only about half as many FSC as those of normal individuals. Whereas, in states of increased iron storage such as seen in sideroblastic anemia, aplastic anemia and myelofibrosis, the mean numbers of FSC are markedly increased to about 4–8 times in PBM, about 11–20 times in lymphocytes and about 3–7 times in monocytes, compared with each counterpart of the normal individuals.

Keywords:
Ferritin-secreting cells, Hematological disorders, Reverse hemolytic plaque assay
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.